2-year Copaxone Treatment in RRMS Found to Slow Loss of Gray Matter
Two years of treatment with the approved therapy >Copaxone (glatiramer acetate) was found to slow the loss of cerebral gray matter and whole brain volume ā two markers of neurodegeneration ā in people with relapsing-remitting multiple sclerosis (RRMS). Notably, individuals on Copaxone…